Our research impact: PARP inhibitors 12 May 2022 To mark our outstanding success in REF2021, Alison Halliday spoke to several of our researchers here at the ICR who were instrumental in the development of PARP inhibitors, a type of targeted drug that’s been approved for use in breast, ovarian and prostate cancer. Find out more Show/Hide
Scientific achievements of 2020/2021 10 Dec 2021 We've selected a range of discoveries from the academic year that highlight the quality and breadth of our basic, translational and clinical research. Find out more Show/Hide
canSAR: The AI ‘knowledgebase’ revolutionising cancer drug discovery 02 Jul 2021 Since its release in 2011, canSAR has become the largest, public, cancer drug discovery resource in the world. On the 10-year anniversary of canSAR we take a look at how it’s shaping the future of drug discovery. Find out more Show/Hide